Jiangsu Sheneryang High-tech Co., Ltd Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2017
NCT03283059
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Jiangsu Sheneryang High-tech Co., Ltd

Active Ingredients

Drugs in Phase 3 Trials (2)

donepezil (aricept) (1 trial)

octohydroaminoacridine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2